Moreover, existing clinical studies have focused primarily on liraglutide, while the effects of other GLP‐1R agonists—such as dulaglutide and semaglutide—remain largely unexamined in the context of OSA. Here, GLP1R is linked to obstructive sleep apnea syndrome.